Quabbe HJ - Search Results

1

Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.

Plöckinger U, Reichel M, Fett U, Saeger W, Quabbe HJ. Plöckinger U, et al. Among authors: quabbe hj. J Clin Endocrinol Metab. 1994 Nov;79(5):1416-23. doi: 10.1210/jcem.79.5.7962337. J Clin Endocrinol Metab. 1994. PMID: 7962337

2

Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.

Plöckinger U, Quabbe HJ. Plöckinger U, et al. Among authors: quabbe hj. Acta Neurochir (Wien). 2005 May;147(5):485-93; discussion 493. doi: 10.1007/s00701-005-0511-9. Epub 2005 Apr 4. Acta Neurochir (Wien). 2005. PMID: 15806331 Clinical Trial.

3

Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.

Quabbe HJ, Plöckinger U. Quabbe HJ, et al. J Clin Endocrinol Metab. 1989 May;68(5):873-81. doi: 10.1210/jcem-68-5-873. J Clin Endocrinol Metab. 1989. PMID: 2565912

4

Octreotide long term treatment of acromegaly: effect of drug withdrawal on serum growth hormone/insulin-like growth factor-I concentrations and on serum gastrin/24-hour intragastric pH values.

Plöckinger U, Liehr RM, Quabbe HJ. Plöckinger U, et al. Among authors: quabbe hj. J Clin Endocrinol Metab. 1993 Jul;77(1):157-62. doi: 10.1210/jcem.77.1.8325938. J Clin Endocrinol Metab. 1993. PMID: 8325938

5

Metabolic aspects of acromegaly and its treatment.

Quabbe HJ, Plöckinger U. Quabbe HJ, et al. Metabolism. 1996 Aug;45(8 Suppl 1):61-2. doi: 10.1016/s0026-0495(96)90084-0. Metabolism. 1996. PMID: 8769384 Review.

6

Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to ocreotide therapy and do not correlate with tumor histology.

Plöckinger U, Bäder M, Hopfenmüller W, Saeger W, Quabbe HJ. Plöckinger U, et al. Among authors: quabbe hj. Eur J Endocrinol. 1997 Apr;136(4):369-76. doi: 10.1530/eje.0.1360369. Eur J Endocrinol. 1997. PMID: 9150695

7

Effect of the somatostatin analog octreotide on gastric mucosal function and histology during 3 months of preoperative treatment in patients with acromegaly.

Plöckinger U, Perez-Canto A, Emde C, Liehr RM, Hopfenmüller W, Quabbe HJ. Plöckinger U, et al. Among authors: quabbe hj. Eur J Endocrinol. 1998 Oct;139(4):387-94. doi: 10.1530/eje.0.1390387. Eur J Endocrinol. 1998. PMID: 9820614

8

Octreotide suppresses the incretin glucagon-like peptide (7-36) amide in patients with acromegaly or clinically nonfunctioning pituitary tumors and in healthy subjects.

Plöckinger U, Holst JJ, Messerschmidt D, Hopfenmüller W, Quabbe HJ. Plöckinger U, et al. Among authors: quabbe hj. Eur J Endocrinol. 1999 Jun;140(6):538-44. doi: 10.1530/eje.0.1400538. Eur J Endocrinol. 1999. PMID: 10377503 Clinical Trial.

9

Evaluation of a repeatable depot-bromocriptine preparation(Parlodel LAR) for the treatment of acromegaly.

Plöckinger U, Quabbe HJ. Plöckinger U, et al. Among authors: quabbe hj. J Endocrinol Invest. 1991 Dec;14(11):943-8. doi: 10.1007/BF03347120. J Endocrinol Invest. 1991. PMID: 1806612 Clinical Trial.

10

Gastrointestinal side-effects of octreotide during long-term treatment of acromegaly.

Plöckinger U, Dienemann D, Quabbe HJ. Plöckinger U, et al. Among authors: quabbe hj. J Clin Endocrinol Metab. 1990 Dec;71(6):1658-62. doi: 10.1210/jcem-71-6-1658. J Clin Endocrinol Metab. 1990. PMID: 2229321

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

61 results

Search Page

Filters